AlexanderNoorShoushtariMD

Physician

Overview of Dr. Shoushtari

Medical Oncology
Melanoma Service, Memorial Sloan Kettering Cancer Center

My clinical and translational research focus is in developing therapies for rare melanoma subtypes (uveal, mucosal, and acral melanoma).

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(719) 285-9971

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
University of ChicagoResidency, Internal Medicine, 2009 - 2012
Rush Medical College of Rush University Medical CenterClass of 2009

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2021 - 2025
NY State Medical License 2012 - 2025
IL State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Treating Patients With Melanoma and ALK Alterations With Ensartinib Start of enrollment: 2018 Jan 10
Active, not recruiting
Phase 2
FHD-286 in Subjects With Metastatic Uveal Melanoma Start of enrollment: 2021 May 11
Terminated
Phase 1
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Start of enrollment: 2022 May 17
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Start of enrollment: 2022 Jul 04
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of LN-144 in People With Metastatic Melanoma to the Brain Start of enrollment: 2022 Nov 25
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Start of enrollment: 2022 Nov 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.
Michael V Gormally, Monica F Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds
JAMA Oncology. 2024-11-27
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma.
Matthew R Kudelka, Allison L Richards, Philip Friedlander, Jedd D Wolchok, Andrea P Moy
Journal for Immunotherapy of Cancer. 2024-11-17
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.
Sarah E Lochrin, Darren J Buonocore, Robert J Young, Thomas J Kaley, Michael A Postow
Pigment Cell & Melanoma Research. 2024-11-01

Lectures

Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas.
2019 ASCO Annual Meeting - 6/1/2019
Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Immunocore Presents Data at the European Society for Medical Oncology (ESMO) Congress 2021 Demonstrating a Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical TrialSeptember 20th, 2021
Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated with ErdafitinibOctober 29th, 2020
Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal MelanomaJune 22nd, 2020
Join now to see all